Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Paramyxoviridae Infections Clear all
Completed Phase 2 Interventional Results available

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

NCT05568706
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MMR and Varicella Vaccine in Premature Infants

NCT00156559
View directory record Official record
Conditions
Chickenpox, Rubella, Rubeola, Mumps
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Months to 16 Months
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 4, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

NCT05964582
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 21 Months
Enrollment
344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

NCT06601192
View directory record Official record
Conditions
RSV Infection, QTc Interval
Interventions
zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Lenexa, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

NCT06221813
View directory record Official record
Conditions
Nipah Virus Infection
Interventions
PHV02, Lactated Ringer's
Biological
Lead sponsor
Public Health Vaccines LLC
Industry
Eligibility
18 Years to 59 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Anaheim, California • Hollywood, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group

NCT00000815
View directory record Official record
Conditions
HIV Infections, Measles
Interventions
Attenuvax, M-M-R-II
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 7 Months
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
43
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01489306
View directory record Official record
Conditions
Drug Safety
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 4, 2026, 10:33 PM EDT
Not listed No phase listed Observational

FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

NCT05928507
View directory record Official record
Conditions
Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
Interventions
Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
Diagnostic Test
Lead sponsor
Baebies, Inc.
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT02952339
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 1030s vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

NCT05118386
View directory record Official record
Conditions
RSV Infection
Interventions
RSM01, Placebo
Drug · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01355016
View directory record Official record
Conditions
Drug Safety, Respiratory Syncytial Virus Infections
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

NCT02058563
View directory record Official record
Conditions
Rubella, Mumps, Measles
Interventions
Priorix®, Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
7 Years and older
Enrollment
996 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

NCT01346293
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Measles, Polio
Interventions
Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
3,372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

NCT02247726
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection)
Drug
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
7
States / cities
Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RSV Challenge in Healthy Adults

NCT00100373
View directory record Official record
Conditions
Respiratory Infections, Acute, Respiratory Syncytial Virus
Interventions
RSV challenge material
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Making Decisions About the Measles-Mumps-Rubella Vaccine

NCT01369394
View directory record Official record
Conditions
Measles, Mumps, Rubella, MMR Vaccination
Interventions
Behavioral: Computer-based tailoring system
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

NCT00626327
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Months to 1 Year
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
90
States / cities
Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 4, 2026, 10:33 PM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers

NCT00186927
View directory record Official record
Conditions
Parainfluenza, Respiratory Viral Infections
Interventions
Sendai virus vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 6 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

NCT04919109
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CodaVax-RSV, Normal Saline
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
6 Months to 5 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

NCT06847464
View directory record Official record
Conditions
RSV Infection, Drug Drug Interaction (DDI)
Interventions
EDP-323, Itraconazole, carbamazepine, Quinidine, fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MEDI ΔM2-2 vaccine, Placebo vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05630846
View directory record Official record
Conditions
Measles; Mumps; Rubella; Chickenpox, Measles
Interventions
Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 4, 2026, 10:33 PM EDT